Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with paclitaxel for reimbursement as a treatment option for the treatment of patients with HER2-negative metastatic breast cancer.
This is written in the approval document as:
In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-negative | Invasive Breast Carcinoma | Bevacizumab, Paclitaxel |